What is PTCT's P/E ratio?

PTC THERAPEUTICS INC (PTCT) currently trades at a P/E ratio of 368.62.

PTC THERAPEUTICS INC reports a Return on Equity (ROE) of 103.47%.

What is PTCT's dividend yield?

PTC THERAPEUTICS INC offers a dividend yield of 0.00%.

What is PTCT's Deepscope Quality Score?

Deepscope rates PTCT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PTCT?

Deepscope's AI Timing Score for PTCT is 94 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PTCT belong to?

PTC THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Cổ phiếu PTCT (NASDAQ) | PTC THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

PTCT

PTC THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 94

USD 70.97

0.33 (0.47%) Day Change

Watchlist Portfolio Compare Chart

368.62

P/E

-1.69

D/E

103.5%

ROE

-6.5%

ROA

0.00%

Div Yield

-3.69

PEG

PTC THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 70.97 Price 0.33 (0.47%) Day Change	NEWS SCORE: 94

PTCT Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ P/E tương đối cao
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...

Yếu tố Chất lượng

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	1641
Magic Formula Rank by ROE	1641
Magic Formula Rank by ROIC	1643
Price	70.97
PBV / Sector	-32.47 / 4.63
Earning Per Share	-2.26

PE / Sector	368.62 / 17.43
PEG or PE/Growth / Sector	-3.69 / 0.53
Average 1M Daily Value	99.35 M
Average 1W Daily Value	74.01 M

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-22.58 / 449.48
NPM Average (%) / Sector	-34.99 / -1,506.49
NPM Change Average (%) / Sector	-98.48 / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-6.51 / 30.58
ROA Average (%) / Sector	-14.04 / -347.17
ROA Change Average (%) / Sector	-93.12 / 5,125.52
ROE (%) / Sector	103.47 / -3.58 GREAT
ROE Average (%) / Sector	8.34 / 40.65
ROE Change Average (%) / Sector	-336.33 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

Chi tiết đăng ký

Analyze Date	2026-06-06 09:09:07
Symbol	PTCT
Name	PTC THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	82.95 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,859.54 / 8,857.28

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059

Phone: 908 222 7000

Website: https://www.ptcbio.com

Employees: 991

Sector: Healthcare >> Biotechnology

Description: PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.